The study was aimed at evaluating the role of DBH, DRD2, MAOA, BDNF, COMT, SLC6A4, SLC6A3, ACE, DRD1 gene polymorphisms in the development of ICD in PD patients receiving dopaminergic therapy. This evidence concerns the gene DBH and Parkinson disease.